Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with Relatlimab or Ipilimumab in Resectable Head and Neck Cancer
NCT04080804Phase 2Active, not recruiting
- Start
- Dec 2019
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, relatlimab, ipilimumab in head and neck squamous cell carcinoma (HNSCC). Started Dec 2019; status: active, not recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04080804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04080804.